- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03392324
PRIMA US-Feasibility Study in Atrophic Dry AMD (PRIMA-FS-US)
January 23, 2024 updated by: Pixium Vision SA
Feasibility Study of Compensation for Blindness With the PRIMA System in Patients With Atrophic Dry Age Related Macular Degeneration
In this early feasibility trial the safety and performance of the new retinal prothesis PRIMA is tested in five subjects suffering from atrophic dry age related macular degeneration.
Study Overview
Status
Active, not recruiting
Conditions
Intervention / Treatment
Detailed Description
PRIMA is a new photovoltaic sub-retinal wireless prosthesis for partial restoration of visual perception in patients with vision loss from atrophic dry Age-related Macular Degeneration.
The implantable part of the device is placed under the retina.
A mini camera mounted on a pair of glasses captures the visual scene in the environment.
The visual scene is processed and simplified by the pocket computer connected to the glasses in order to extract useful information from the images.
The simplified images are then sent back to the glasses where a miniaturized projector then projects the processed images wirelessly via pulses of near infrared light on the PRIMA implant at the back of the eye under the retina.
The photovoltaic cells convert this optical information into electrical stimulation to excite the nerve cells of the retina and induce visual perception.
In this early feasibility study five human subjects suffering from atrophic dry age related macular degeneration will receive the implant.
The performance and the safety of the device will be monitored for up to 36 months.
Study Type
Interventional
Enrollment (Actual)
5
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Ralf Hornig, PhD
- Phone Number: 4742 +33 17621
- Email: rhornig@pixium-vision.com
Study Locations
-
-
California
-
Palo Alto, California, United States, 94303
- Byers Eye Institute-Stanford University
-
-
Florida
-
Miami, Florida, United States, 33136
- Bascom Palmer Eye Institute
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15213
- UPMC Eye Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
60 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Is 60 years or older at the date of inclusion;
- Has a confirmed diagnosis of atrophic dry age related macular degeneration with an atrophy size of at least 3 optic disc diameters in the study eye;
- Has best corrected visual acuity of logMAR 1.3 (20/400) or worse in the study eye measured by ETDRS;
- Has a central scotoma in the study eye with no perception at 0 dB on MP-1 micro-perimetry scale in the visual field covering the central 7 degrees (+/-3.5 degrees) and maximum 20% perception in the remaining visual field covering the central 12 degrees (+/- 6 degrees);
Meets one of the following criteria in the non-study eye:
- Visual acuity of 20/200 (logMAR 1.0) or worse and an atrophy size <8mm2
- Visual acuity of 20/160 (logMAR 0.9) or worse and an atrophy size ≥8mm2 and ≤12.5 mm2
- Visual acuity of 20/100 (logMAR 0.7) or worse and an atrophy size >12.5 mm2
- Has a refraction of study eye between -3 and + 4 (limits included) for patients with IOL (there is no refraction criteria for phakic patients);
- Understands and accepts the obligation to present for all schedule follow-up visits;
- Patient signed informed consent.
Main Exclusion Criteria:
- Has cataract in the study ;
- Has an aphakic study eye;
- Has no light perception in the study eye;
- Has a history of choroidal neovascularization in either eye;
- Has any disease (other than study allowed diseases) or condition that affects retinal function of the study eye
- Has an implanted telescope in one eye;
- Has any disease or condition that prevents adequate examination of the study
- Has a corneal endothelial cell count of less than 1000 cells/mm² in the study eye
- Suffers from nystagmus or other ocular motility disorders;
- Has any disease or condition that precludes the understanding or communication of the informed consent, study requirements or test protocols
- Has a history of epileptic seizure;
- Has a history of chronic or recurrent infection or inflammation that would preclude participation in the study;
- Presents with hypotony or hypertony in the study eye;
- Has another active implanted device;
- Has active cancer or a history of intraocular, optic nerve or brain cancer and metastasis;
- Is an immune-suppressed subject;
- Is carrier of multi-resistant microorganisms;
- Is receiving anticoagulation therapy that cannot be adapted to allow eye surgery;
- Is participating in another investigational drug or device study that may interfere with the present study;
- Has recurrent or chronic inflammations or infections;
- Has a severe psychological disorder;
- Does not have the mental capacity to legally sign the informed consent;
- Has severe renal, cardiac, hepatic, etc. organ diseases;
- Has head dimensions that are incompatible with the Visual Interface;
- Has too high and unrealistic expectation;
Detailed patient criteria will be verified by the study doctor.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: PRIMA
Implantation of PRIMA device
|
Implantation of PRIMA device
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Near Visual Acuity
Time Frame: 12 months after implantation
|
Near Visual acuity measured by FrACT
|
12 months after implantation
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Near Visual Acuity
Time Frame: 3, 6, 9, 18, 24, and 36 months after implantation
|
Near Visual acuity measured by FrACT
|
3, 6, 9, 18, 24, and 36 months after implantation
|
Visual Acuity
Time Frame: 3, 6, 9, 12, 18, 24 and 36 months after implantation
|
Visual acuity measured by ETDRS
|
3, 6, 9, 12, 18, 24 and 36 months after implantation
|
Reading Acuity Test
Time Frame: 6, 12, 24, 36 months after implantation
|
Reading acuity measured by Radner Charts
|
6, 12, 24, 36 months after implantation
|
Quality of Life
Time Frame: 12, 24, and 36 months after implantation
|
The change in quality of life is measure by the Impact of Vision Impairment (IVI) Questionnaire
|
12, 24, and 36 months after implantation
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Joseph Martel, MD, UPMC Pittsburgh
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
April 26, 2018
Primary Completion (Estimated)
December 1, 2025
Study Completion (Estimated)
December 1, 2025
Study Registration Dates
First Submitted
December 29, 2017
First Submitted That Met QC Criteria
December 29, 2017
First Posted (Actual)
January 5, 2018
Study Record Updates
Last Update Posted (Actual)
January 24, 2024
Last Update Submitted That Met QC Criteria
January 23, 2024
Last Verified
January 1, 2024
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CIP-PRIMA-FS-US
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Dry Age-related Macular Degeneration
-
Luxa Biotechnology, LLCNational Eye Institute (NEI); National Institutes of Health (NIH); Regenerative...RecruitingDry Age-related Macular DegenerationUnited States
-
CHABiotech CO., LtdTerminatedDry Age Related Macular DegenerationKorea, Republic of
-
Smilebiotek Zhuhai LimitedActive, not recruitingDry Age-related Macular DegenerationUnited States
-
Chinese Academy of SciencesBeijing Tongren HospitalUnknownDry Age-related Macular DegenerationChina
-
Apheresis Research InstituteCompletedDry Age Related Macular DegenerationGermany
-
i-Lumen Scientific, Inc.WithdrawnDry Age-related Macular Degeneration
-
Chinese Academy of SciencesThe First Affiliated Hospital of Zhengzhou UniversityUnknownDry Age-related Macular DegenerationChina
-
CHA UniversityUnknownDry Age Related Macular DegenerationKorea, Republic of
-
LumiThera, Inc.RecruitingDry Age-related Macular DegenerationNorway
-
LumiThera, Inc.National Eye Institute (NEI)RecruitingDry Age-related Macular DegenerationUnited States
Clinical Trials on PRIMA
-
Pixium Vision SAActive, not recruitingDry Age-related Macular DegenerationFrance
-
Fralex TherapeuticsPharmaNetTerminatedChronic Musculoskeletal Pain
-
Syneron MedicalUnknown
-
Fralex TherapeuticsPharmaNet; McDougall Scientific LimitedTerminatedPain | FibromyalgiaUnited States, Canada
-
Pixium Vision SAActive, not recruitingGeographic AtrophyGermany, France, Italy, Netherlands, Spain, United Kingdom
-
Limacorporate S.p.aIqvia Pty LtdNot yet recruitingArthroplasty | Replacement | Shoulder
-
Groupe Francophone des MyelodysplasiesAprea TherapeuticsUnknownChronic Myelomonocytic Leukemia | Myeloproliferative Neoplasm | Acute Myeloid Leukemia With Gene Mutations | Myelodysplastic Syndrome With Gene MutationFrance
-
H. Lee Moffitt Cancer Center and Research InstituteAprea TherapeuticsCompletedAcute Myeloid Leukemia | Chronic Myelomonocytic Leukemia | Myelodysplastic Syndrome | Myeloproliferative NeoplasmUnited States
-
M.D. Anderson Cancer CenterWithdrawnRecurrent Mantle Cell Lymphoma | Refractory Mantle Cell LymphomaUnited States
-
Candela CorporationCompletedErythematotelangiectatic RosaceaUnited States